

# Novel simple conjugation chemistries for decoration of GMMA with heterologous antigens

Roberta Di Benedetto <sup>1</sup>, Renzo Alfini <sup>1</sup>, Martina Carducci <sup>1</sup>, Maria Grazia Aruta <sup>1</sup>, Luisa Lanzilao <sup>1#</sup>, Alessandra Acquaviva <sup>1</sup>, Elena Palmieri <sup>1</sup>, Carlo Giannelli <sup>1</sup>, Francesca Necchi <sup>1</sup>, Allan Saul <sup>1†</sup> and Francesca Micoli <sup>1,\*</sup>

<sup>1</sup> GSK Vaccines Institute for Global Health (GVGH), Via Fiorentina 1, 53100 Siena, Italy; [roberta.x.di-benedetto@gsk.com](mailto:roberta.x.di-benedetto@gsk.com) (R.D.B.); [renzo.x.alfini@gsk.com](mailto:renzo.x.alfini@gsk.com) (R.A.); [martina.x.carducci@gsk.com](mailto:martina.x.carducci@gsk.com) (M.C.); [maria-grazia.x.aruta@gsk.com](mailto:maria-grazia.x.aruta@gsk.com) (M.G.A.); [lanzilaol@aou-careggi.toscana.it](mailto:lanzilaol@aou-careggi.toscana.it) (L.L.); [alessandra.x.acquaviva@gsk.com](mailto:alessandra.x.acquaviva@gsk.com) (A.A.); [elena.x.palmieri@gsk.com](mailto:elena.x.palmieri@gsk.com) (E.P.); [carlo.x.giannelli@gsk.com](mailto:carlo.x.giannelli@gsk.com) (C.G.), [francesca.x.necchi@gsk.com](mailto:francesca.x.necchi@gsk.com) (F.N.), [allan.saul@honorary.burnet.edu.au](mailto:allan.saul@honorary.burnet.edu.au) (A.S.)

# Was GSK employee at the time of the study was performed, currently General Laboratory, AOU-Careggi, 50139 Firenze, Italy

† Was GSK employee at the time of the study was performed, currently Burnet Institute, Melbourne, Australia

\* Correspondence: [francesca.x.micoli@gsk.com](mailto:francesca.x.micoli@gsk.com) (F.M.); Tel.: +39 346 2517893

**Table S1.** DoE approach applied to GMMA oxidation: summary of conditions tested.

Std	Run	Factor 1	Factor 2	Factor 3
		A:[GMMA] mg/mL	B:[NaIO <sub>4</sub> ] mM	C:pH
19	1	2100	2.75	6.5
14	2	2100	2.75	8
2	3	4000	0.5	5
13	4	2100	2.75	5
3	5	200	5	5
18	6	2100	2.75	6.5
9	7 <sup>1</sup>	200	2.75	6.5
10	8	4000	2.75	6.5
12	9	2100	5	6.5
16	10	2100	2.75	6.5
11	11	2100	0.5	6.5
1	12	200	0.5	5
15	13	2100	2.75	6.5
17	14	2100	2.75	6.5
5	15	200	0.5	8
7	16	200	5	8
20	17	2100	2.75	6.5
8	18	4000	5	8
6	19	4000	0.5	8
4	20	4000	5	5

<sup>1</sup> There was an error during the execution of this run..

Starting GMMA having particle size of 51.6 nm (r. by dls) and OAg length of 30564 Da (by HPLC-SEC).

**(a)**

**Response** **OAg size (MP dRI)**

These rows were ignored for this analysis.

7

**ANOVA for Response Surface Reduced 2FI model**

**Analysis of variance table [Partial sum of squares - Type III]**

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F
Model	8.41E+08	4	2.10E+08	74.540	< 0.0001 <i>significant</i>
A-[GMMA]	8.29E+07	1	8.29E+07	29.370	< 0.0001
B-[NaIO <sub>4</sub> ]	7.16E+08	1	7.16E+08	253.860	< 0.0001
C-pH	2.66E+07	1	2.66E+07	9.430	0.008
AB	1.55E+07	1	1.55E+07	5.500	0.034
Residual	3.95E+07	14	2.82E+06		
Lack of Fit	3.35E+07	9	3.72E+06	3.110	0.112 <i>not significant</i>
Pure Error	5.99E+06	5	1.20E+06		
Cor Total	8.81E+08	18			

Std. Dev.	1679.610	R-Squared	0.955
Mean	20888.950	Adj R-Squared	0.942
C.V. %	8.040	Pred R-Squared	0.898
PRESS	9.01E+07	Adeq Precision	30.493
-2 Log Likelihood	330.320	BIC	345.040
		AICc	344.930

**Final Equation in Terms of Actual Factors:**

$$\begin{aligned}
 \text{OAg size (MP dRI)} = & 22521.574070 \\
 & 0.705910 * [\text{GMMA}] \\
 & -4445.173680 * [\text{NaIO}_4] \\
 & 1087.400000 * \text{pH} \\
 & 0.325700 * [\text{GMMA}] * [\text{NaIO}_4]
 \end{aligned}$$

(b)

**Figure S1.** Identification of optimal conditions for GMMA oxidation: statistical analysis of the models for % GMMA oxidation (a) and OAg size (b)

**Table S2.** DoE approach applied to GMMA activation with BS3: summary of conditions tested.

Block	Run	Factor 1	Factor 2	Factor 3
		pH	[GMMA]	BS3 concentration (eq BS3 to NH <sub>2</sub> on GMMA)
			mg/mL	mg/mL (eq)
Day 1	1	6	0.2	1.2 (5)
Day 1	2	9	0.2	3.6 (15)
Day 1	3	7.5	2.1	25.2 (10)
Day 1	4	9	4	72.1 (15)
Day 1	5	9	0.2	1.2 (5)
Day 1	6	6	4	72.1 (15)
Day 1	7	6	4	24 (5)
Day 1	8	7.5	2.1	25.2 (10)
Day 1	9	7.5	2.1	25.2 (10)
Day 1	10	9	4	24 (5)
Day 1	11	6	0.2	3.6 (15)
Day 1	12	7.5	2.1	25.2 (10)
Day 2	13	7.5	2.1	12.6 (5)
Day 2	14	7.5	4	48.1 (10)
Day 2	15	6	2.1	25.2 (10)
Day 2	16	7.5	2.1	25.2 (10)
Day 2	17	7.5	2.1	37.8 (15)
Day 2	18	7.5	0.2	2.4 (10)
Day 2	19	9	2.1	25.2 (10)
Day 2	20	7.5	2.1	25.2 (10)

**% NH2 activation (TNBS)**

**Analysis of variance table [Partial sum of squares - Type III]**

Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F
Block	128.1687	1	128.1687011		
Model	1735.712	10	173.5711605	53.46789	3.15E-06 <i>significant</i>
A-pH	308.1359	1	308.1359333	94.92002	1.03E-05
B-[GMMA]	738.1734	1	738.1733798	227.3913	3.7E-07
C-eq BS3 to NH2 on GMMA	241.241	1	241.2409902	74.3133	2.54E-05
AB	41.05079	1	41.05079148	12.64553	0.007443
AC	0.074411	1	0.074411136	0.022922	0.883408
BC	35.64661	1	35.6466111	10.98079	0.010639
A^2	73.11089	1	73.11088939	22.52151	0.001453
B^2	25.36879	1	25.36879225	7.814753	0.02336
C^2	15.60412	1	15.60412436	4.806787	0.059694
ABC	38.12519	1	38.12518624	11.74431	0.008995
Residual	25.97015	8	3.246269198		
Lack of Fit	15.38771	4	3.846926685	1.454078	0.362811 <i>not significant</i>
Pure Error	10.58245	4	2.645611711		
Cor Total	1889.85	19			

Std. Dev.	1.801741	R-Squared	0.985258
Mean	51.63048	Adj R-Squared	0.966831
C.V. %	3.489684	Pred R-Squared	0.70962
PRESS	511.5576	Adeq Precision	30.43426
-2 Log Likelihood	61.98185	BIC	97.93064
		AICc	130.5533

% NH<sub>2</sub> activation =

```
-141.803
  40.1702 * pH
11.40516 * [GMMA]
4.953846 * eq BS3 to NH2 on GMMA
-0.73713 * pH * [GMMA]
-0.33457 * pH * eq BS3 to NH2 on GMMA
-0.92677 * [GMMA] * eq BS3 to NH2 on GMMA
-2.31953 * pH^2
  -0.8516 * [GMMA]^2
-0.09644 * eq BS3 to NH2 on GMMA^2
0.153196 * pH * [GMMA] * eq BS3 to NH2 on GMMA
```

**(a)**

**Response** **% active ester groups (HPLC-SEC)**

These rows were ignored for this analysis.

10

**ANOVA for Response Surface Reduced Quadratic model**

**Analysis of variance table [Partial sum of squares - Type III]**


Source	Sum of Squares	df	Mean Square	F Value	p-value Prob > F
Block	328.6142	1	328.6141536		
Model	673.5975	5	134.7195007	9.402123	0.000778 <i>significant</i>
A-pH	12.15521	1	12.15521342	0.848317	0.375175
B-[GMMA]	225.14	1	225.1400244	15.7126	0.00188
C-eq BS3 to NH2 on GMMA	244.837	1	244.8370265	17.08727	0.001386
A^2	126.9122	1	126.9122129	8.85725	0.011569
C^2	165.231	1	165.2309933	11.53153	0.005311
Residual	171.9435	12	14.32862531		
Lack of Fit	129.8367	8	16.22958835	1.541755	0.356404 <i>not significant</i>
Pure Error	42.1068	4	10.52669924		
Cor Total	1174.155	18			
Std. Dev.	3.785317		R-Squared	0.796647	
Mean	19.33909		Adj R-Squared	0.711916	
C.V. %	19.5734		Pred R-Squared	0.45243	
PRESS	462.9929		Adeq Precision	11.9817	
-2 Log Likelihood	95.77148		BIC	116.3825	
			AICc	119.9533	

**Final Equation in Terms of Actual Factors:**


gruppi reattivi / GMMA  
 143.4041  
 -44.1813 \* pH  
 2.703501 \* [GMMA]  
 7.011795 \* eq BS3 to NH2 on GMMA  
 2.892371 \* pH^2  
 -0.29702 \* eq BS3 to NH2 on GMMA^2

(b)


**Figure S2.** Identification of optimal conditions for GMMA derivatization with BS3: statistical analysis of the models for % NH<sub>2</sub> activation (a) and % active ester groups introduced (b). Row 10 was ignored in (b) as the sample was erroneously poured out before analysis.




**Figure S3.** Characterization by WB analysis of GMMA-R06C and GMMA-fHbp v2 conjugates produced by reductive amination and BS3 chemistries respectively in comparison to corresponding unconjugated proteins. Ten  $\mu\text{g}$  of conjugates and 2  $\mu\text{g}$  of protein were loaded per well. Lane 1: marker, lane 2: STm GMMAox-R06C recycled, lane 3: R06C, lane 4: STm GMMAox-R06C, lane 5: fHbp v2, lane 6: STm GMMA-BS3-fHbp v2, lane 7: STm GMMA-BS3-fHbp v2 recycled.



**Figure S4.** Immunogenicity of R06C-GMMA conjugates (reductive amination chemistry) in mice. CD1 mice were immunized subcutaneously at day 0 and 28 with 36  $\mu\text{g}$  and 56  $\mu\text{g}$  total protein dose (corresponding to 4  $\mu\text{g}$  R06C/dose) for the R06C non-recycled and recycled conjugates respectively. All constructs were formulated with 0.7 mg/mL Alhydrogel. Sera were analyzed at days -1, 14, 27 and 42 by ELISA using as coating antigen STm OAg. Summary graphs of anti-antigen specific IgG geometric mean units (bars) and individual antibody levels (dots) are reported.




(a)



(b)

**Figure S5.** Bivalent conjugate characterization by WB and dls analyses. (a) WB analysis of the conjugate in comparison to corresponding unconjugated proteins. Ten  $\mu\text{g}$  of conjugate and 2  $\mu\text{g}$  of proteins were loaded per well. Lane 1: marker, lane 2: FdeC, lane 3: orthogonal bivalent conjugate, lane 4: SsIE. (b) dls analysis of *S. sonnei* GMMA (red line, Z average r of 56.3 nm, PdI of 0.197), *S. sonnei* GMMA-BS3 (green line, Z average r of 58.1 nm, PdI of 0.409) and bivalent conjugate (blue line, Z average r of 51.4 nm, PdI of 0.316), confirming no crosslinking after conjugation.



**Figure S6.** Vicinal diols, in STm GMMA OAg, which are susceptible to oxidation with  $\text{NaIO}_4$ : present at the Rha and Glc residues, highlighted in green.